Sudair Pharma proudly participated in the signing of a major national agreement between Sanofi, NUPCO, and strategic Saudi partners aimed at localizing insulin production in the Kingdom of Saudi Arabia. The event took place on 22 October 2024 under the patronage of high-ranking government leaders in the health and industrial sectors.
This landmark agreement supports the localization of vital pharmaceutical products, strengthens national drug security, and contributes to the transformation of Saudi Arabia into a regional hub for healthcare innovation. As part of the initiative, technology transfer from Sanofi will enable the production of high-quality insulin within the Kingdom, ensuring sustainable supply and advancing national self-sufficiency.
Sudair Pharma’s participation reflects its commitment to:
Supporting national pharmaceutical localization strategies,
Enabling advanced manufacturing capabilities,
Contributing to Saudi Vision 2030 healthcare transformation,
Collaborating with leading global and governmental partners.
The ceremony was attended by key government officials, including representatives from the Ministry of Health, the Ministry of Industry and Mineral Resources, the Ministry of Investment, the Local Content and Government Procurement Authority, and NUPCO.
The partnership marks a major step toward enhancing the Kingdom’s readiness in critical medicines and empowering local production with global expertise.
Sudair Pharma expressed its pride in contributing to this strategic initiative, reaffirming its commitment to advancing Saudi Arabia’s pharmaceutical sector and ensuring high-quality, accessible healthcare solutions for the community.
